A recurrent mutation in PALB2 in Finnish cancer families - PubMed (original) (raw)
. 2007 Mar 15;446(7133):316-9.
doi: 10.1038/nature05609. Epub 2007 Feb 7.
Bing Xia, Jenni Nikkilä, Johanna Schleutker, Kirsi Syrjäkoski, Arto Mannermaa, Anne Kallioniemi, Katri Pylkäs, Sanna-Maria Karppinen, Katrin Rapakko, Alexander Miron, Qing Sheng, Guilan Li, Henna Mattila, Daphne W Bell, Daniel A Haber, Mervi Grip, Mervi Reiman, Arja Jukkola-Vuorinen, Aki Mustonen, Juha Kere, Lauri A Aaltonen, Veli-Matti Kosma, Vesa Kataja, Ylermi Soini, Ronny I Drapkin, David M Livingston, Robert Winqvist
Affiliations
- PMID: 17287723
- DOI: 10.1038/nature05609
A recurrent mutation in PALB2 in Finnish cancer families
Hannele Erkko et al. Nature. 2007.
Abstract
BRCA1, BRCA2 and other known susceptibility genes account for less than half of the detectable hereditary predisposition to breast cancer. Other relevant genes therefore remain to be discovered. Recently a new BRCA2-binding protein, PALB2, was identified. The BRCA2-PALB2 interaction is crucial for certain key BRCA2 DNA damage response functions as well as its tumour suppression activity. Here we show, by screening for PALB2 mutations in Finland that a frameshift mutation, c.1592delT, is present at significantly elevated frequency in familial breast cancer cases compared with ancestry-matched population controls. The truncated PALB2 protein caused by this mutation retained little BRCA2-binding capacity and was deficient in homologous recombination and crosslink repair. Further screening of c.1592delT in unselected breast cancer individuals revealed a roughly fourfold enrichment of this mutation in patients compared with controls. Most of the mutation-positive unselected cases had a familial pattern of disease development. In addition, one multigenerational prostate cancer family that segregated the c.1592delT truncation allele was observed. These results indicate that PALB2 is a breast cancer susceptibility gene that, in a suitably mutant form, may also contribute to familial prostate cancer development.
Similar articles
- Analysis of FANCB and FANCN/PALB2 fanconi anemia genes in BRCA1/2-negative Spanish breast cancer families.
García MJ, Fernández V, Osorio A, Barroso A, Llort G, Lázaro C, Blanco I, Caldés T, de la Hoya M, Ramón Y Cajal T, Alonso C, Tejada MI, San Román C, Robles-Díaz L, Urioste M, Benítez J. García MJ, et al. Breast Cancer Res Treat. 2009 Feb;113(3):545-51. doi: 10.1007/s10549-008-9945-0. Epub 2008 Feb 27. Breast Cancer Res Treat. 2009. PMID: 18302019 - Penetrance analysis of the PALB2 c.1592delT founder mutation.
Erkko H, Dowty JG, Nikkilä J, Syrjäkoski K, Mannermaa A, Pylkäs K, Southey MC, Holli K, Kallioniemi A, Jukkola-Vuorinen A, Kataja V, Kosma VM, Xia B, Livingston DM, Winqvist R, Hopper JL. Erkko H, et al. Clin Cancer Res. 2008 Jul 15;14(14):4667-71. doi: 10.1158/1078-0432.CCR-08-0210. Clin Cancer Res. 2008. PMID: 18628482 - The breast cancer susceptibility mutation PALB2 1592delT is associated with an aggressive tumor phenotype.
Heikkinen T, Kärkkäinen H, Aaltonen K, Milne RL, Heikkilä P, Aittomäki K, Blomqvist C, Nevanlinna H. Heikkinen T, et al. Clin Cancer Res. 2009 May 1;15(9):3214-22. doi: 10.1158/1078-0432.CCR-08-3128. Epub 2009 Apr 21. Clin Cancer Res. 2009. PMID: 19383810 - Discovering moderate-risk breast cancer susceptibility genes.
Hollestelle A, Wasielewski M, Martens JW, Schutte M. Hollestelle A, et al. Curr Opin Genet Dev. 2010 Jun;20(3):268-76. doi: 10.1016/j.gde.2010.02.009. Epub 2010 Mar 24. Curr Opin Genet Dev. 2010. PMID: 20346647 Review. - Prevalent mutations in prostate cancer.
Dong JT. Dong JT. J Cell Biochem. 2006 Feb 15;97(3):433-47. doi: 10.1002/jcb.20696. J Cell Biochem. 2006. PMID: 16267836 Review.
Cited by
- Comprehensive Analysis of Adverse Events Induced by PARP Inhibitors Using JADER and Time to Onset.
Yamaoka K, Fujiwara M, Uchida M, Uesawa Y, Muroi N, Shimizu T. Yamaoka K, et al. Life (Basel). 2022 Aug 31;12(9):1355. doi: 10.3390/life12091355. Life (Basel). 2022. PMID: 36143391 Free PMC article. - Contribution of the PALB2 c.2323C>T [p.Q775X] founder mutation in well-defined breast and/or ovarian cancer families and unselected ovarian cancer cases of French Canadian descent.
Tischkowitz M, Sabbaghian N, Hamel N, Pouchet C, Foulkes WD, Mes-Masson AM, Provencher DM, Tonin PN. Tischkowitz M, et al. BMC Med Genet. 2013 Jan 9;14:5. doi: 10.1186/1471-2350-14-5. BMC Med Genet. 2013. PMID: 23302520 Free PMC article. - Activation of recombinational repair in Ewing sarcoma cells carrying EWS-FLI1 fusion gene by chromosome translocation.
Tanaka K, Suzuki K, Miyashita K, Wakasa K, Kawano M, Nakatsu Y, Tsumura H, Yoshida MA, Oda S. Tanaka K, et al. Sci Rep. 2022 Aug 30;12(1):14764. doi: 10.1038/s41598-022-19164-x. Sci Rep. 2022. PMID: 36042341 Free PMC article. - Prevalence of PALB2 mutations in Australasian multiple-case breast cancer families.
Teo ZL, Park DJ, Provenzano E, Chatfield CA, Odefrey FA, Nguyen-Dumont T; kConFab; Dowty JG, Hopper JL, Winship I, Goldgar DE, Southey MC. Teo ZL, et al. Breast Cancer Res. 2013 Feb 28;15(1):R17. doi: 10.1186/bcr3392. Breast Cancer Res. 2013. PMID: 23448497 Free PMC article. - PALB2 is an integral component of the BRCA complex required for homologous recombination repair.
Sy SM, Huen MS, Chen J. Sy SM, et al. Proc Natl Acad Sci U S A. 2009 Apr 28;106(17):7155-60. doi: 10.1073/pnas.0811159106. Epub 2009 Apr 15. Proc Natl Acad Sci U S A. 2009. PMID: 19369211 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous